XNAS · Healthcare · Biotechnology
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
Innovation platform company reports catastrophic **$-790.49 EPS** with microscopic $12K revenue. Stakeholder collaboration model failing to generate meaningful commercial traction.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | — | -790.49 | — | $12,159 | — | +2.86% | -85.36% | — |
| 2026-03-31 | Q4 2025 | — | -1214.00 | — | $425,000 | — | -6.33% | -46.93% | -80.08% |
| 2025-11-18 |
| Q3 2025 |
| — |
| -548.78 |
| — |
| $748,000 |
| — |
| — |
| — |
| — |
| 2025-03-31 | Q4 2024 | — | -2539.65 | — | $3,175 | — | +0.78% | -17.06% | -50.72% |
| 2024-11-18 | Q3 2024 | — | -111.07 | — | $6,854 | — | +3.24% | +17.99% | -29.50% |
| 2024-08-19 | Q2 2024 | — | -167.60 | — | $44,276 | — | -16.67% | -30.47% | -60.88% |
| 2024-05-20 | Q1 2024 | — | -365.60 | — | $79,680 | — | -0.48% | -3.83% | -29.19% |
| 2024-04-16 | Q4 2023 | -1192.40 | -603.85 | +49.36% | $81,297 | ✅ Beat | -3.29% | -6.58% | -17.28% |
Showing last 8 quarters.